Nanexa pauses NEX-18 study

Nanexa today announces that the inclusion of patients in the company's phase I study with NEX-18, a depot formulation of 5-azacitidine, is paused due to moderate skin reactions at the injection site.

The moderate skin reactions that have occured differ slightly from the mild reaction that normally occurs after the administration of 5-azacitidine. To clarify the cause, Nanexa together with the clinics is conducting an investigation including biopsies of the affected skin. The investigation is expected to be concluded in Q4 2021.

"The pause in inclusion is done with the patients' best interests in mind. We will return as soon as we have more information about what caused these moderate skin reactions and about how we proceed with the study," said Nanexa's CEO David Westberg.

The study preliminarily shows that PharmaShell works as expected when it comes to creating a beneficial pharmacokinetic profile, which is in line with what has been shown in the preclinical studies. The interruption has no effect on the planning and preparation of Nanexa's other clinical project, NEX-20, with lenalidomide in multiple myeloma, or on ongoing partner activities. The work of selecting the next drug candidate for NEX-21 is also proceeding according to plan.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, a new and groundbreaking drug delivery system with great potential for a number of medical substance types and indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with several pharma companies, among others AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

This information is information that Nanexa is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-09-24 19:30 CEST.

Attachments

Nanexa pauses NEX-18 study